Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 8/20 | 0.38 |
| ▸ | HTR2C | P28335 | 8/20 | 0.38 |
| ▸ | HTR2B | P41595 | 6/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.36 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24852110 | 0.84 | IDO1 (0.41) | IDO1PYCR1S1PR1DAO | |
| SCHEMBL17071829 | 0.81 | HTR2A (0.36) | IDO1HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL30151183 | 0.81 | KIF11 (0.42) | IDO1HTR2AHTR2CHTR2BPYCR1 | |
| SCHEMBL24852109 | 0.81 | KIF11 (0.42) | IDO1HTR2AHTR2CHTR2BPYCR1 | |
| SCHEMBL13557209 | 0.80 | HTR2A (0.40) | HTR2AHTR2CHTR2BCYP3A4SIGMAR1 | |
| SCHEMBL20656678 | 0.78 | HTR2A (0.39) | HTR2AHTR2CHTR2BCYP3A4SIGMAR1 | |
| SCHEMBL13804350 | 0.77 | IDO1 (0.36) | IDO1HTR2AHTR2CHTR2BCYP3A4 | |
| SCHEMBL17069252 | 0.75 | HTR2A (0.33) | HTR2AHTR2CHTR2BHTR1ADRD2 | |
| SCHEMBL257057 | 0.74 | DAO (0.48) | IDO1SIGMAR1PYCR1LMNADAO | |
| SCHEMBL257060 | 0.74 | IDO1 (0.61) | IDO1PYCR1LMNAS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210252014-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS INC (US) | 2021-08-19 | — | — | US | disclosed |
| US-10987359-B2 | Oxadiazepinone derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200197408-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987359-B2 | Oxadiazepinone derivatives and methods of treating hepatitis B infections | HCCS, SLC10A1, PYGL | IDO1 549/4885HTR2A 3030/4885HTR2C 2588/4885 |
| US-20210252014-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | IDO1 543/4885HTR2A 2140/4885HTR2C 2158/4885 |
| US-20200197408-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HCCS, SLC10A1, PYGL | IDO1 549/4885HTR2A 3030/4885HTR2C 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.